Skip to main content

Table 4 Overview of anti-pituitary adenylate cyclase-activating polypeptide/pituitaryadenylate cyclase 1 (PACAP/PAC1) monoclonal antibodies

From: Therapeutic novelties in migraine: new drugs, new hope?

Drug Target Administration Interval between administrations Status
ALD1910 Ligand N/A N/A Preclinical phase
AMG-301 Receptor Subcutaneous injection 4 weeks Phase II clinical trials
\